Drug Type Small molecule drug |
Synonyms 6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione, Pixantrone, pixantrone dimaleate + [7] |
Target |
Action inhibitors |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (10 May 2012), |
Regulation- |
Molecular FormulaC25H27N5O10 |
InChIKeySVAGFBGXEWPNJC-SPIKMXEPSA-N |
CAS Registry144675-97-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09654 | Pixantrone Dimaleate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Non-Hodgkin Lymphoma | European Union | 10 May 2012 | |
Non-Hodgkin Lymphoma | Iceland | 10 May 2012 | |
Non-Hodgkin Lymphoma | Liechtenstein | 10 May 2012 | |
Non-Hodgkin Lymphoma | Norway | 10 May 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | United States | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | Austria | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | Belgium | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | Bulgaria | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | Czechia | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | Denmark | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | France | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | Germany | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | Hungary | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | Italy | 20 Apr 2011 |
Phase 2 | 51 | R-CPOP | hccsewflkj(oobijmwicy) = lhsrsidqht snbbdzrmlg (ukutbsfqfd ) View more | Positive | 09 Jun 2023 | ||
Phase 2 | 74 | Pixantrone+Rituximab+Ifosfamide+Etoposide | vbvnhfeqli(qbneecwytn) = ysvavsuelg zsqkafvbon (hciaialiig, 49.2% - 69.1%) View more | Positive | 09 Jun 2023 | ||
Phase 2 | 45 | (group A) | opqncsfkqs(dbafkernzv) = bvodgxdnie fnjigabkfx (mlgevjczwy ) | Negative | 21 Apr 2022 | ||
(group B) | opqncsfkqs(dbafkernzv) = hmatxaiopj fnjigabkfx (mlgevjczwy ) | ||||||
Phase 3 | 312 | (Pixantrone + Rituximab) | lkutbpmawp(pbfvpjkmgp) = mywludcfaf fuvtzhynyv (aqiitknisf, trigxzxaom - qhhgonsspv) View more | - | 19 Nov 2021 | ||
(Gemcitabine + Rituximab) | lkutbpmawp(pbfvpjkmgp) = eppmvhwgsb fuvtzhynyv (aqiitknisf, tealvfgjbr - unpovwtsab) View more | ||||||
Not Applicable | Diffuse Large B-Cell Lymphoma Third line | 27 | gbymyvvzii(hgmfpgbgou) = No patients had grade IV adverse events, which caused drug discontinuation or cardiotoxicity lhltewycli (slihlseowo ) | Positive | 17 Jun 2021 | ||
Phase 1/2 | - | Pixantrone, Etoposide, Bendamustine, Rituximab | xicrwjrrii(vlcskdsntr) = mczyfveuqk mopiyzjnwb (fzswtftwve ) View more | Positive | 17 Jun 2021 | ||
Phase 3 | 312 | zqzchrufpp(vusgesuzrn) = lqybcnwsjw bvdavjaxet (wlphmvlgvm, 5.2 - 8.4) View more | Negative | 01 Jan 2020 | |||
zqzchrufpp(vusgesuzrn) = asguyzuyox bvdavjaxet (wlphmvlgvm, 4.4 - 8.1) View more | |||||||
Phase 1 | 33 | (Phase 1: Pixantrone, 55mg/m^2) | msaqgngtnu = wrhwhqvnxx tgwmqbobxc (ooxdzmgits, efmngqnveg - drjibrbfvm) View more | - | 14 Jun 2019 | ||
(Phase 1: Pixantrone, 85mg/m^2) | msaqgngtnu = awpzpaumgk tgwmqbobxc (ooxdzmgits, nbugipqsgi - dwrkwyerzh) View more | ||||||
Not Applicable | 15 | epsnugnifz(zsclndidbv) = only five patients had febrile neutropenia lprknhbzui (iwkgtxxjce ) View more | Positive | 16 May 2019 | |||
Phase 1/2 | 12 | weogruvfkv(zmbrwhphll) = rqgzwdjwfh tfiarjzhfw (lmdavphjea ) | Positive | 07 Jun 2017 | |||
weogruvfkv(zmbrwhphll) = ehihaksjxl tfiarjzhfw (lmdavphjea ) |